We were retained by counsel for an international pharmaceutical company in connection with a proposed Internal Revenue Service transfer-pricing adjustment. We prepared summaries of financial and other quantitative information spanning a 30-year period (entity-level and product-line financial statements). This information was the basis for negotiating stipulated facts, and it supported other accounting and economic experts.